Ovarian Hypertension: Polycystic Ovary Syndrome
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Hypertension is a significant contributor to the risk for cardiovascular disease. The increased prevalence of hypertension in women with polycystic ovary syndrome (PCOS) may contribute to the increased risk of cardiovascular disease in these women. Whether hypertension is associated with PCOS independent of obesity remains controversial. Nevertheless, detection and subsequent treatment of hypertension in this population should decrease the adverse sequelae from hypertensive cardiovascular disease. Treatment of risk factors inherent to PCOS, such as hyperandrogenism, insulin resistance, and obesity, may minimize the risk not only for the development of hypertension but also for incident cardiovascular disease independent of hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121
Comment on the provisional report from the WHO consultation
(1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00059.x · Cited by 1,820
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Self-citationNorman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61345-2 · Cited by 1,360
Androgen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132
American College of Endocrinology Position Statement on the Insulin Resistance Syndrome
Einhorn, D. (2003) · Endocrine Practice · doi:10.4158/ep.9.s2.5 · Cited by 1,066
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010
Inflammation in Atherosclerosis: Transition From Theory to Practice
Libby, P., Okamoto, Y., Rocha, V. Z., & Folco, E. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0706 · Cited by 799
Menstrual cycle irregularity and risk for future cardiovascular disease
Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer, F. E., & Manson, J. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8471 · Cited by 528
Self-citationCarmina, E., & Lobo, R. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5803 · Cited by 528
Talbott, E. O., Guzick, D. S., Sutton-Tyrrell, K., McHugh-Pemu, K. P., Zborowski, J. V., Remsberg, K. E., & Kuller, L. H. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.11.2414 · Cited by 511
Polycystic ovary syndrome and cardiovascular disease: a premature association?
Legro, R. S. (2003) · Endocrine Reviews · doi:10.1210/er.2003-0004 · Cited by 466
Ehrmann, D. A., Sturis, J., Byrne, M. M., Karrison, T., Rosenfield, R. L., & Polonsky, K. S. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118064 · Cited by 426
Nelson, V. L., Qin, K.-N., Rosenfield, R. L., Wood, J. R., Penning, T. M., Legro, R. S., Strauss, J. F., & McAllister, J. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8088 · Cited by 405
Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS)
Dunaif, A., Wu, X., Lee, A., & Diamanti-Kandarakis, E. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.2.e392 · Cited by 337
Self-citationThe role of lifestyle modification in polycystic ovary syndrome
Norman, R. J., Davies, M. J., Lord, J., & Moran, L. J. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(02)00612-4 · Cited by 326
Overweight Women with Polycystic Ovary Syndrome Have Evidence of Subclinical Cardiovascular Disease
Meyer, C., McGrath, B. P., & Teede, H. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0011 · Cited by 273
Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?
Sverrisdóttir, Y. B., Mogren, T., Kataoka, J., Janson, P. O., & Stener-Victorin, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00725.2007 · Cited by 216
Research works printed but not linked: 97
- Burghen, 1980, Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease, J Clin Endocrinol Metab, 50, 113, 10.1210/jcem-50-1-113 · DOI · Paper page
- Dunaif, 1987, Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia, J Clin Endocrinol Metab, 65, 499, 10.1210/jcem-65-3-499 · DOI · Paper page
- Dunaif, 1997, Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis, Endocr Rev, 18, 774
- Ehrmann, 2005, Polycystic ovary syndrome, N Engl J Med, 352, 1223, 10.1056/NEJMra041536 · DOI · Paper page
- Polson, 1988, Polycystic ovaries—a common finding in normal women, Lancet, 1, 870, 10.1016/S0140-6736(88)91612-1 · DOI · Paper page
- Legro, 2005, Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype, J Clin Endocrinol Metab, 90, 2571, 10.1210/jc.2004-0219 · DOI · Paper page
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil Steril, 81, 19, 10.1016/j.fertnstert.2003.10.004 · DOI · Paper page
- Robinson, 1993, The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries, Clin Endocrinol (Oxf), 39, 351, 10.1111/j.1365-2265.1993.tb02376.x · DOI · Paper page
- Adams, 2004, Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome, J Clin Endocrinol Metab, 89, 4343, 10.1210/jc.2003-031600 · DOI · Paper page
- Azziz, 2004, The prevalence and features of the polycystic ovary syndrome in an unselected population, J Clin Endocrinol Metab, 89, 2745, 10.1210/jc.2003-032046 · DOI · Paper page
- Asunción, 2000, A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain, J Clin Endocrinol Metab, 85, 2434
- Diamanti-Kandarakis, 1999, A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile, J Clin Endocrinol Metab, 84, 4006, 10.1210/jcem.84.11.6148 · DOI · Paper page
- Moran, 2010, Prevalence of polycystic ovary syndrome and related disorders in Mexican women, Gynecol Obstet Invest, 69, 274, 10.1159/000277640 · DOI · Paper page
- Knochenhauer, 1998, Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study, J Clin Endocrinol Metab, 83, 3078
- Lo, 2006, Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome, J Clin Endocrinol Metab, 91, 1357, 10.1210/jc.2005-2430 · DOI · Paper page
- Marshall, 1999, Neuroendocrine aspects of polycystic ovary syndrome, Endocrinol Metab Clin North Am, 28, 295, 10.1016/S0889-8529(05)70071-2 · DOI
- Eagleson, 2000, Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone, J Clin Endocrinol Metab, 85, 4047
- Franks, 1989, Polycystic ovary syndrome, Trends Endocrinol Metab, 1, 60, 10.1016/1043-2760(89)90003-9 · DOI
- Reid, 1981, Induction of ovulation and pregnancy with pulsatile luteinizing hormone releasing factor: dosage and mode of delivery, Fertil Steril, 36, 553, 10.1016/S0015-0282(16)45850-4 · DOI
- Legro, 1998, Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome, Proc Natl Acad Sci U S A, 95, 14956, 10.1073/pnas.95.25.14956 · DOI · Paper page
- Wickenheisser, 2000, Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells, J Clin Endocrinol Metab, 85, 2304
- Dunaif, 1999, Insulin action in the polycystic ovary syndrome, Endocrinol Metab Clin North Am, 28, 341, 10.1016/S0889-8529(05)70073-6 · DOI · Paper page
- Book, 1999, Selective insulin resistance in the polycystic ovary syndrome, J Clin Endocrinol Metab, 84, 3110
- Escobar-Morreale, 2005, The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery, J Clin Endocrinol Metab, 90, 6364, 10.1210/jc.2005-1490 · DOI · Paper page
- Laitinen, 2003, Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms, Int J Obes Relat Metab Disord, 27, 710, 10.1038/sj.ijo.0802301 · DOI · Paper page
- Hoeger, 2007, Obesity and lifestyle management in polycystic ovary syndrome, Clin Obstet Gynecol, 50, 277, 10.1097/GRF.0b013e31802f54c8 · DOI · Paper page
- Grodstein, 1994, Body mass index and ovulatory infertility, Epidemiology, 5, 247, 10.1097/00001648-199403000-00016 · DOI · Paper page
- Legro, 2002, Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome, J Clin Endocrinol Metab, 87, 2134, 10.1210/jcem.87.5.8387 · doi:10.1210/jcem.87.5.8387 · Paper page
- Legro, 2002, Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity, J Clin Endocrinol Metab, 87, 2128, 10.1210/jcem.87.5.8513 · doi:10.1210/jcem.87.5.8513 · Paper page
- Urbanek, 1999, Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin, Proc Natl Acad Sci U S A, 96, 8573, 10.1073/pnas.96.15.8573 · DOI · Paper page
- Urbanek, 2000, Allelic variants of the follistatin gene in polycystic ovary syndrome, J Clin Endocrinol Metab, 85, 4455
- Urbanek, 2007, Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype, J Clin Endocrinol Metab, 92, 4191, 10.1210/jc.2007-0761 · DOI · Paper page
- Ewens, 2010, Family-based analysis of candidate genes for polycystic ovary syndrome, J Clin Endocrinol Metab, 95, 2306, 10.1210/jc.2009-2703 · DOI · Paper page
- National Cholesterol Education Program (NCEP) Expert Panel on Detection E and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002, Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 · DOI · Paper page
- Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404 · DOI · Paper page
- Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
- Essah, 2006, Metabolic syndrome in women with polycystic ovary syndrome, Fertil Steril, 86, S18, 10.1016/j.fertnstert.2006.04.013 · DOI
- Sam, 2005, Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 4797, 10.1210/jc.2004-2217 · DOI · Paper page
- Bentley-Lewis, 2007, The metabolic syndrome in women, Nat Clin Pract Endocrinol Metab, 3, 696, 10.1038/ncpendmet0616 · DOI
- Legato, 2000, Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy, Am J Cardiol, 86, 15L, 10.1016/S0002-9149(00)01463-6 · DOI
- Valkenburg, 2008, A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study, J Clin Endocrinol Metab, 93, 470, 10.1210/jc.2007-1756 · DOI · Paper page
- Carmina, 2009, Cardiovascular risk and events in polycystic ovary syndrome, Climacteric, 12, 22, 10.1080/13697130903003842 · DOI · Paper page
- Conway, 1992, Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome, Clin Endocrinol (Oxf), 37, 119, 10.1111/j.1365-2265.1992.tb02295.x · DOI · Paper page
- Talbott, 1998, Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study, J Clin Epidemiol, 51, 415, 10.1016/S0895-4356(98)00010-9 · DOI · Paper page
- Vrbíková, 2003, Cardiovascular risk factors in young Czech females with polycystic ovary syndrome, Hum Reprod, 18, 980, 10.1093/humrep/deg218 · DOI · Paper page
- Elting, 2001, Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population, Hum Reprod, 16, 556, 10.1093/humrep/16.3.556 · DOI · Paper page
- Holte, 1996, Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?, Hum Reprod, 11, 23, 10.1093/oxfordjournals.humrep.a019028 · DOI · Paper page
- Orbetzova, 2003, Role of 24-hour monitoring in assessing blood pressure changes in polycystic ovary syndrome, Folia Med (Plovdiv), 45, 21
- Wild, 2000, Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study, Hum Fertil (Camb), 3, 101, 10.1080/1464727002000198781 · DOI · Paper page
- Dahlgren, 1992, Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones, Fertil Steril, 57, 505, 10.1016/S0015-0282(16)54892-4 · DOI · Paper page
- Farquhar, 2007, Laparoscopic ‘drilling’ by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD001122.pub3 · DOI · Paper page
- Buttram, 1975, Post-ovarian wedge resection adhesive disease, Fertil Steril, 26, 874, 10.1016/S0015-0282(16)41351-8 · DOI
- Barcellos, 2007, Impact of body mass index on blood pressure levels in patients with polycystic ovary syndrome, Arq Bras Endocrinol Metabol, 51, 1104, 10.1590/S0004-27302007000700013 · DOI · Paper page
- Arslanian, 2001, Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease, J Clin Endocrinol Metab, 86, 66
- Luque-Ramírez, 2007, Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome, J Clin Endocrinol Metab, 92, 2141, 10.1210/jc.2007-0190 · DOI · Paper page
- Zimmermann, 1992, Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance, J Clin Endocrinol Metab, 75, 508
- Sampson, 1996, Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome, Clin Endocrinol (Oxf), 45, 623, 10.1046/j.1365-2265.1996.00863.x · DOI · Paper page
- Cibula, 2000, Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome, Hum Reprod, 15, 785, 10.1093/humrep/15.4.785 · DOI · Paper page
- Boomsma, 2008, Pregnancy complications in women with polycystic ovary syndrome, Semin Reprod Med, 26, 72, 10.1055/s-2007-992927 · DOI · Paper page
- Ludwig, 2005, Risk during pregnancy and birth after assisted reproductive technologies: an integral view of the problem, Semin Reprod Med, 23, 363, 10.1055/s-2005-923394 · DOI
- Sun, 2009, Assisted reproductive technology and placenta-mediated adverse pregnancy outcomes, Obstet Gynecol, 114, 818, 10.1097/AOG.0b013e3181b76bd1 · DOI
- Möhlig, 2004, The polycystic ovary syndrome per se is not associated with increased chronic inflammation, Eur J Endocrinol, 150, 525, 10.1530/eje.0.1500525 · DOI · Paper page
- Escobar-Morreale, 2003, Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women, Diabetologia, 46, 625, 10.1007/s00125-003-1090-z · DOI
- Ketel, 2008, Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance, J Clin Endocrinol Metab, 93, 3365, 10.1210/jc.2008-0626 · DOI · Paper page
- Ketel, 2010, Greater arterial stiffness in polycystic ovary syndrome (PCOS) is an obesity—but not a PCOS-associated phenomenon, J Clin Endocrinol Metab, 95, 4566, 10.1210/jc.2010-0868 · DOI · Paper page
- Spranger, 2004, Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome, Clin Endocrinol (Oxf), 61, 738, 10.1111/j.1365-2265.2004.02159.x · DOI · Paper page
- Lindholm, 2010, Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome, Gynecol Endocrinol, 26, 743, 10.3109/09513590.2010.487592 · DOI
- Guzick, 1996, Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study, Am J Obstet Gynecol, 174, 1224, 10.1016/S0002-9378(96)70665-8 · DOI · Paper page
- Luque-Ramírez, 2007, Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome, Hum Reprod, 22, 3197, 10.1093/humrep/dem324 · DOI · Paper page
- Carmina, 2006, Endothelial dysfunction in PCOS: role of obesity and adipose hormones, Am J Med, 119, 356.e1, 10.1016/j.amjmed.2005.10.059 · DOI · Paper page
- Christian, 2003, Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 88, 2562, 10.1210/jc.2003-030334 · DOI · Paper page
- Talbott, 2004, Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome, J Clin Endocrinol Metab, 89, 5454, 10.1210/jc.2003-032237 · DOI · Paper page
- Talbott, 2008, Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women?, Vasc Health Risk Manag, 4, 453, 10.2147/VHRM.S1452 · DOI · Paper page
- Chen, 2007, Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome, Hypertension, 49, 1442, 10.1161/HYPERTENSIONAHA.106.083972 · DOI · Paper page
- Riccioni, 2009, The effect of antihypertensive drugs on carotid intima media thickness: an up-to-date review, Curr Med Chem, 16, 988, 10.2174/092986709787581923 · doi:10.2174/092986709787581923
- Zavaroni, 1995, Association between salt sensitivity and insulin concentrations in patients with hypertension, Am J Hypertens, 8, 855, 10.1016/0895-7061(95)00152-F · DOI
- Resnick, 1992, Cellular ions in hypertension, insulin resistance, obesity, and diabetes: a unifying theme, J Am Soc Nephrol, 3, S78, 10.1681/ASN.V34s78 · DOI
- Lord, 2003, Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome, Cochrane Database Syst Rev, 3
- Diamanti-Kandarakis, 2007, Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome, Metabolism, 56, 129, 10.1016/j.metabol.2006.09.006 · DOI
- Hattori, 2002, Vascular smooth muscle cell activation by glycated albumin (Amadori adducts), Hypertension, 39, 22, 10.1161/hy1201.097300 · DOI · Paper page
- Orio, 2005, Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study, J Clin Endocrinol Metab, 90, 6072, 10.1210/jc.2005-0965 · DOI · Paper page
- Kannel, 2000, Fifty years of Framingham study contributions to understanding hypertension, J Hum Hypertens, 14, 83, 10.1038/sj.jhh.1000949 · DOI · Paper page
- Cupisti, 2008, Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome, Eur J Endocrinol, 158, 711, 10.1530/EJE-07-0515 · DOI · Paper page
- Glintborg, 2004, Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis, Fertil Steril, 82, 1570, 10.1016/j.fertnstert.2004.06.040 · DOI
- Yildirir, 2006, Heart rate variability in young women with polycystic ovary syndrome, Ann Noninvasive Electrocardiol, 11, 306, 10.1111/j.1542-474X.2006.00122.x · DOI · Paper page
- Muniyappa, 2007, Cardiovascular actions of insulin, Endocr Rev, 28, 463, 10.1210/er.2007-0006 · DOI · Paper page
- Müller-Wieland, 1998, Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance, Basic Res Cardiol, 93, 131, 10.1007/s003950050238 · DOI
- Battaglia, 2010, Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study, Fertil Steril, 94, 1417, 10.1016/j.fertnstert.2009.05.044 · DOI
- Kriplani, 2010, Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome, Contraception, 82, 139, 10.1016/j.contraception.2010.02.009 · DOI
- Fruzzetti, 2010, Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome, Fertil Steril, 94, 1793, 10.1016/j.fertnstert.2009.10.016 · DOI
- Guido, 2004, Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study, J Clin Endocrinol Metab, 89, 2817, 10.1210/jc.2003-031158 · DOI · Paper page
- Ober, 1978, Spironolactone therapy for hirsutism in a hyperandrogenic woman, Ann Intern Med, 89, 643, 10.7326/0003-4819-89-5-643 · DOI
- Rathnayake, 2010, Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss, Dermatol Clin, 28, 611, 10.1016/j.det.2010.03.011 · DOI
- Christy, 2005, Spironolactone for hirsutism in polycystic ovary syndrome, Ann Pharmacother, 39, 1517, 10.1345/aph.1G025 · DOI
- Ganie, 2004, Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study, J Clin Endocrinol Metab, 89, 2756, 10.1210/jc.2003-031780 · DOI · Paper page
- Armanini, 2007, Treatment of polycystic ovary syndrome with spironolactone plus licorice, Eur J Obstet Gynecol Reprod Biol, 131, 61, 10.1016/j.ejogrb.2006.10.013 · DOI
- Eid, 2005, Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass, Surg Obes Relat Dis, 1, 77, 10.1016/j.soard.2005.02.008 · DOI · Paper page
Cited by
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030
Vogel, B., Acevedo, M., Appelman, Y., Bairey Merz, C. N., Chieffo, A., Figtree, G. A., Guerrero, M., Kunadian, V., Lam, C. S. P., Maas, A. H. E. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00684-x · Cited by 1,488
Epidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
The pathogenesis and treatment of polycystic ovary syndrome: What’s new?
Bednarska, S., & Siejka, A. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/59380 · Cited by 284
Hung, J.-H., Hu, L.-Y., Tsai, S.-J., Yang, A. C., Huang, M.-W., Chen, P.-M., Wang, S.-L., Lu, T., & Shen, C.-C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097041 · Cited by 152
“Recently, it has been postulated that PCOS is linked to an increased risk for cardiovascular diseases [3] and type 2 diabetes [4] in affected women.”
BackgroundNikokavoura, E., Johnston, K. L., Broom, J., Wrieden, W., & Rolland, C. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s85134 · Cited by 26
Metadata
- Authors
- Bentley-Lewis, R., Seely, E., & Dunaif, A.
- Venue
- Endocrinology and Metabolism Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 40
- Issue
- 2
- Pages
- 433-449
- ISSN
- 0889-8529 (ISSN-L)
- OpenAlex
- W1989897876
- Cited by
- 78
- References
- 20
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.